Efficacy of TCA Effect on Varicella Atrophic Scars

Atrophic Varicella Scar Clinical Trial

Official title:

Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00422539
• Other study ID #: SRC-BBA-1385-6-1
• Status: Recruiting
• Phase: Phase 2
• First received: January 16, 2007
• Last updated: January 16, 2007
• Start date: March 2006

Study information

• Verified date: January 2007
• Source: hahid Beheshti University of Medical Sciences
• Contact: Behrooz Barikbin, M.D.
• Phone: 98-21-22744393
• Email: bbarikbin[@]yahoo.com
• Is FDA regulated: No
• Health authority: Iran: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella

Description:

high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 15 Years to 45 Years

Eligibility

Inclusion Criteria:

• Atrophic varicella scar on face

Exclusion Criteria:

• Active varicella infection

• Active Herpetic infection

• Previous history of keloid formation

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atrophic Varicella Scar
• Atrophy
• Chickenpox
• Herpes Zoster

Intervention

Drug:
• 70% trichloroacetic acid

Locations

Country	Name	City	State
Iran, Islamic Republic of	Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Clearance(before and after photographies were taken)
Secondary	Subjective Clearance(according to the patients satisfaction)
Secondary	Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)